Skip to main content
. Author manuscript; available in PMC: 2024 Mar 11.
Published in final edited form as: J Med Chem. 2021 May 18;64(10):6949–6971. doi: 10.1021/acs.jmedchem.1c00491

Figure 4.

Figure 4.

Optimization of dual activity of TZD-analogues against HDAC4 and HDAC8. P19 is a moderate HDAC8 selective inhibitor,53 3k52 shows improved activity on both, HDAC4 and HDAC8, and 7w shows high activity against both HDAC enzymes.